Bright Minds Biosciences Inc Cash Flow Conversion Efficiency
Bright Minds Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has a cash flow conversion efficiency ratio of -0.027x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.42 Million) by net assets ($308.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bright Minds Biosciences Inc (2019–2025)
Cash flow conversion efficiency of Bright Minds Biosciences Inc from 2019 to 2025. This chart illustrates how Bright Minds Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bright Minds Biosciences Inc stock quote for real-time trading data and today's change.
Bright Minds Biosciences Inc Cash Flow Conversion Ratio Explained
Bright Minds Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bright Minds Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bright Minds Biosciences Inc ranked by their cash flow conversion efficiency. Also see DRUG market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HIL Limited
NSE:HIL
|
0.049x |
|
SPACSphere Acquisition Corp. Class A Ordinary Shares
NASDAQ:SSAC
|
0.000x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
|
Bicycle Therapeutics plc
F:50BA
|
-0.097x |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
0.024x |
|
Brightcom Group Limited
NSE:BCG
|
0.003x |
|
Sekerbank TAS
IS:SKBNK
|
0.497x |
|
Hammond Manufacturing Company Limited
TO:HMM-A
|
0.060x |
Annual Cash Flow Conversion Efficiency for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bright Minds Biosciences Inc from 2019 to 2025. Review Bright Minds Biosciences Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $82.04 Million | $-8.69 Million | -0.106x | +68.30% |
| 2024-09-30 | $5.54 Million | $-1.85 Million | -0.334x | +68.61% |
| 2023-09-30 | $6.60 Million | $-7.02 Million | -1.065x | +17.40% |
| 2022-09-30 | $10.54 Million | $-13.59 Million | -1.289x | -241.63% |
| 2021-09-30 | $19.40 Million | $-7.32 Million | -0.377x | +4.60% |
| 2020-09-30 | $729.29K | $-288.39K | -0.395x | -19.80% |
| 2019-09-30 | $127.26K | $-42.01K | -0.330x | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more